肝细胞癌尿液代谢组学研究
采用超高效液相色谱-四极杆飞行时间质谱检测健康对照、肝血管瘤患者和肝细胞癌患者各10例尿液小分子代谢物,共鉴定381种差异代谢物,其中55种与肝细胞癌特异相关,主要富集于谷氨酰胺/谷氨酸代谢、赖氨酸生物合成、三羧酸循环和嘌呤代谢通路。
要点
- 肝细胞癌、肝血管瘤与健康对照三组尿液代谢谱存在差异,共鉴定381种差异代谢物。
- 与肝细胞癌特异相关的尿液代谢物55种,其中21种上调、34种下调。
- 差异代谢物主要富集于谷氨酰胺/谷氨酸代谢、赖氨酸生物合成、三羧酸循环和嘌呤代谢通路。
核心结论
- 肝细胞癌发生过程中伴随多种代谢物和代谢途径改变,分析尿液特征代谢谱有助于发现肝癌的代谢标志物和潜在治疗靶点。
研究设计与样本
- 采用超高效液相色谱-四极杆飞行时间质谱检测健康对照(n=10)、肝血管瘤患者(n=10)和肝细胞癌患者(n=10)尿液中的小分子代谢物。
- 采用正交偏最小二乘法-判别分析、层次聚类分析和单因素分析等方法分析三组人群尿液代谢物差异。
主要发现
- 三组共鉴定差异代谢物381种,其中上调96种、下调285种。
- 与肝细胞癌特异相关的尿液代谢物55种,包括21种显著上调代谢物(如Acetyl-DL-Leucine、Ala Asp、HoPhe-Gly-OH等)和34种显著下调代谢物(如Selenocystathionine、Met Trp Met Cys、Valsartan acid等)。
- 京都基因与基因组百科全书通路分析显示差异代谢物主要富集于谷氨酰胺/谷氨酸代谢、赖氨酸生物合成、三羧酸循环和嘌呤代谢等通路。
关键数值与推荐
- 健康对照、肝血管瘤患者和肝细胞癌患者各10例。
- 差异代谢物381种,其中上调96种、下调285种。
- 肝细胞癌特异相关尿液代谢物55种,其中上调21种、下调34种。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To investigate the urinary small molecular metabolites and their metabolic characteristics of patients with hepatocellular carcinoma (HCC). Methods: High throughput ultra-performance liquid chromatography-quadrupole time-of-flight mass spectrometry (UPLC-Q-TOF-MS) was used to detect the small molecular metabolites in urine of healthy control (n=10), patients with hepatic hemangioma (n=10) and patients with HCC (n=10). The orthogonal projections to latent structures-discriminant analysis (OPLS-DA), hierarchical cluster analysis of multivariate analysis and univariate analysis were used to analyze the differential metabolites of the three groups. Results: The metabolic profiles of the three groups showed that the total of 381 differential metabolites were identified and divided into 96 up-regulated metabolites and 285 down-regulated metabolites. There were 55 urinary metabolites specifically related to HCC. Twenty-one of them were significantly up-regulated, including Acetyl-DL-Leucine, Ala Asp, HoPhe-Gly-OH, while 34 were significantly down-regulated, including Selenocystathionine, Met Trp Met Cys, Valsartan acid and so on. Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis showed that the differential metabolites were mainly enriched in glutamine/glutamate metabolism, lysine biosynthesis, tricarboxylic acid cycle and purine metabolism. Conclusions: The occurrence of HCC is accompanied by the abnormalities of multiple metabolites and metabolic pathways. The analysis of the characteristic metabolic profile of urine in patients with HCC is helpful to find metabolic markers and potential therapeutic targets for liver cancer. 目的: 探讨肝细胞癌(HCC)患者尿液小分子代谢物及其代谢特征。 方法: 采用超高效液相色谱-四极杆飞行时间质谱技术分析健康人群(n=10)、肝血管瘤患者(n=10)和HCC患者(n=10)尿液中的小分子代谢物。采用正交偏最小二乘法-判别分析和层次聚类分析以及单因素分析等方法分析全组人群的尿液代谢物产物差异。 结果: 全组人群中,差异代谢物381种,其中上调的代谢物96种,下调的代谢物285种。与HCC有关的特异性尿液代谢物55种,包括21种上调的代谢物,如Acetyl-DL-Leucine、Ala Asp、HoPhe-Gly-OH等,以及34种下调的代谢物,如Selenocystathionine、Met Trp Met Cys、Valsartan acid等。京都基因与基因组百科全书通路分析显示,差异代谢物主要富集于谷氨酰胺/谷氨酸代谢、赖氨酸生物合成、三羧酸循环和嘌呤代谢等通路。 结论: HCC发生过程中伴随多种代谢物和代谢途径改变,分析HCC患者尿液的特征代谢谱,有助于发现肝癌的代谢标志物和潜在的治疗靶点。.
引用
- Xie XF, Sun Y, Zhao XH, et al. [Urine metabolomics study of hepatocellular carcinoma]. Zhonghua Zhong Liu Za Zhi. 2022. PMID: 35316875. doi:10.3760/cma.j.cn112152-20200825-00765
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。